First published May 1, 2013 - More info
Chromosomal instability (CIN) in tumors is characterized by chromosomal abnormalities and an altered gene expression signature; however, the mechanism of CIN is poorly understood. CCND1 (which encodes cyclin D1) is overexpressed in human malignancies and has been shown to play a direct role in transcriptional regulation. Here, we used genome-wide ChIP sequencing and found that the DNA-bound form of cyclin D1 occupied the regulatory region of genes governing chromosomal integrity and mitochondrial biogenesis. Adding cyclin D1 back to Ccnd1–/– mouse embryonic fibroblasts resulted in CIN gene regulatory region occupancy by the DNA-bound form of cyclin D1 and induction of CIN gene expression. Furthermore, increased chromosomal aberrations, aneuploidy, and centrosome abnormalities were observed in the cyclin D1–rescued cells by spectral karyotyping and immunofluorescence. To assess cyclin D1 effects in vivo, we generated transgenic mice with acute and continuous mammary gland–targeted cyclin D1 expression. These transgenic mice presented with increased tumor prevalence and signature CIN gene profiles. Additionally, interrogation of gene expression from 2,254 human breast tumors revealed that cyclin D1 expression correlated with CIN in luminal B breast cancer. These data suggest that cyclin D1 contributes to CIN and tumorigenesis by directly regulating a transcriptional program that governs chromosomal stability.
Mathew C. Casimiro, Marco Crosariol, Emanuele Loro, Adam Ertel, Zuoren Yu, William Dampier, Elizabeth A. Saria, Alex Papanikolaou, Timothy J. Stanek, Zhiping Li, Chenguang Wang, Paolo Fortina, Sankar Addya, Aydin Tozeren, Erik S. Knudsen, Andrew Arnold, Richard G. Pestell
Original citation: J. Clin. Invest. 2012;122(3):833–843. doi:10.1172/JCI60256.
Citation for this corrigendum: J. Clin. Invest. 2013;123(5):2332. doi:10.1172/JCI70042.
The authors inadvertently omitted a funding source from the Acknowledgments section. The correct Acknowledgments section is below.
This work was supported in part by Susan G. Komen Breast Cancer Foundation awards BCTR0504227 (to C. Wang) and PDF2000167 (to A. Arnold); by NIH grants R01CA70896, R01CA75503, R01CA86072, and R01CA13749 (to R.G. Pestell), R01CA55909 (to A. Arnold), and R01CA12934 (to E.S. Knudsen); by the China Scholarship Council; by a Pennsylvania Department of Health grant (to C. Wang and R.G. Pestell); and by the Murray-Heilig Fund in Molecular Medicine (to A. Arnold). Work conducted at the Kimmel Cancer Center was supported by NIH Cancer Center Core grant P30CA56036 (to R.G. Pestell). The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions.
The authors regret the error.